By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. – IBRX
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Technology > ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. – IBRX
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of 0,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. – IBRX
Technology

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. – IBRX

GlobeNews Wire
Last updated: 07/05/2026 8:37 AM
GlobeNews Wire
Published: 07/05/2026
Share
SHARE

NEW ORLEANS, May 06, 2026 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a securities class action lawsuit against ImmunityBio, Inc. (NasdaqGS: IBRX) (“ImmunityBio” or the “Company”), if they purchased or otherwise acquired the Company’s securities between January 19, 2026 and March 24, 2026, inclusive (the “Class Period”).  This action is pending in the United States District Court for the Central District of California.

Get Help

ImmunityBio investors should visit us at https://claimsfiler.com/cases/nasdaq-ibrx-1/?prs=globe or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

About the Lawsuit

ImmunityBio and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.  

On March 24, 2026, a warning letter dated March 13, 2026, from the U.S. Food and Drug Administration to CEO Richard Adcock was made public, stating that a television advertisement and podcast misrepresented Anktiva and resulted in its distribution violating the Federal Food, Drug, and Cosmetic Act. The letter also reportedly noted that the violations “are concerning from a public health perspective because the promotional communications create a misleading impression that Anktiva, a treatment for a certain type of bladder cancer, can cure and even prevent all cancer.”

On this news, the price of ImmunityBio’s shares fell $1.98 per share, or 21%, to close at $7.42 per share on March 24, 2026.

The case is Douglas v. ImmunityBio, Inc., et al., No. 26-cv-03261.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com.

CEO confidence in revenue outlook hits five-year low – as AI becomes a defining divide between leaders and laggards: PwC 2026 Global CEO Survey
Sceye Completes Historic 12-Day, 6,400 Mile Stratospheric Flight, Advancing a New Layer of Infrastructure for Humanity
Jameson Connects gets Mumbai groovin’ to Baby J and Tye Turner
Nanjing Jiangbei New Area Issues Global Call for Talents
Nobel Prize 2025 in Medicine: Three Scientists Who Changed the Future of Immunology
TAGGED:100,000actionAdventureagainstalert:claimsfilerclassdeadlineexcessibrximmunitybio,inc.investorslawsuit,leadlossesnewsplaintiffremindsshareholderwith
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Yakima Chief Hops Launches Latest Pink Boots Blend, Strengthening Education and Gender Diversity in Fermentation
News

Yakima Chief Hops Launches Latest Pink Boots Blend, Strengthening Education and Gender Diversity in Fermentation

09/12/2025
Maris-Tech Announces Financial Results for the Six Months Ended June 30, 2025
Chainguard Launches Global Partner Program to Accelerate Trusted Open Source Software Adoption
Roches Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine)
Thinkrr.ai Advances Its Voice AI Strategy Under CMO Cody Getchell Amid Growing Demand for AI-Driven Automation
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?